arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Arcus Biosciences, Inc.

RCUS
$17.69 ▼ -1.61 (-8.32%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
11 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcus Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield —
Revenue Growth -4.3% ↘
Op. Margin -156.3% ↘
ROIC -52.9% ↗
FCF / Share $-4.51 ↘
Trailing P/E —
Price / Book 3.5x
FCF Yield —
Debt / Equity 0.16
info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$247.00M
↓ -4.3% —
Net Income Profit after all expenses
$-353.00M
↓ -24.7% —
Operating Margin Operating profit as % of sales
-156.3%
↓ -22.2% 1th
FCF / Share Free cash flow per share
$-4.51
↓ -130.7% —
Long-Term Debt Long-term obligations
$99.00M
↑ +106.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
15
Financial Health ↑
47
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 40 quarters